EFICAC-TTR Trial: Exercise and Nutritional Supplementation in Transthyretin Cardiac Amyloidosis (EFICAC-TTR)

September 22, 2026 updated by: Universidad de Burgos

A Prospective, Randomized, Multicenter Clinical Trial on the Effect of a Home-Based Multicomponent Exercise Program Combined With Nutritional Supplementation in Patients With Transthyretin Cardiac Amyloidosis

Transthyretin cardiac amyloidosis (TTR-CA) is a systemic cardiac disease that predominantly affects older adults and is frequently associated with reduced physical capacity, muscle weakness, frailty, and impaired quality of life. Although disease-modifying treatments can slow cardiac disease progression, functional and nutritional impairment remain important unmet clinical needs.

EFICAC-TTR is a prospective, randomized, multicenter study designed to evaluate the effects of a 12-week home-based multicomponent exercise program combined with nutritional supplementation in adults aged 70 years or older with confirmed TTR-CA.

A total of 47 participants were randomized to one of three parallel groups: (1) usual medical care; (2) a home-based multicomponent exercise program plus microcrystalline cellulose control supplementation; or (3) the same exercise program plus creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day).

The primary functional outcomes are change in 6-minute walk test distance and handgrip strength from baseline to 12 weeks. Secondary outcomes include body composition, frailty, quality of life, and nutritional and clinical variables. Mechanistic biomarkers are assessed as exploratory outcomes.

The study aims to determine whether combining exercise with nutritional supplementation can improve functional capacity and related health outcomes in older adults with TTR-CA.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Participants were randomized to three parallel study groups. The usual-care group continued standard clinical management without a structured exercise program or study supplementation. Participants in the two exercise groups performed the same 12-week home-based multicomponent exercise program adapted to individual functional capacity.

In addition to exercise, one group received daily microcrystalline cellulose as a control supplement, whereas the experimental group received creatine monohydrate (3 g/day) plus beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day). The supplement comparison was blinded, while the comparison with usual care was necessarily open because of the behavioral intervention. Functional outcomes were assessed at baseline and after 12 weeks.

Biological samples collected at baseline and after the intervention are used for exploratory mechanistic analyses.

Study Type

Interventional

Enrollment (Actual)

47

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Castille and León
      • Aranda de Duero, Castille and León, Spain
        • Hospital Santos Reyes
      • Burgos, Castille and León, Spain, 09006
        • Hospital Universitario de Burgos
      • Soria, Castille and León, Spain
        • Hospital Santa Bárbara

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

70 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥70 years.
  • Confirmed diagnosis of transthyretin cardiac amyloidosis (TTR-CA) based on positive bone scintigraphy with diphosphonates (Perugini grade 2 or 3) and absence of monoclonal protein.
  • Clinical stability during the 4 weeks prior to enrollment.
  • Ability to understand the study procedures and provide written informed consent.

Exclusion Criteria:

  • Light-chain (AL) amyloidosis or other non-TTR amyloidosis variants.
  • Absolute medical contraindication to moderate-intensity exercise.
  • Severe comorbid conditions with an estimated life expectancy <6 months.
  • Severe cognitive impairment (Mini-Mental State Examination score <20).
  • Concurrent participation in another clinical trial or structured exercise program.
  • Known allergy or intolerance to creatine, beta-hydroxy-beta-methylbutyrate (HMB), or microcrystalline cellulose.
  • Severe renal impairment requiring dialysis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Usual Care

Participants received usual medical care for transthyretin cardiac amyloidosis, including routine cardiology follow-up and general lifestyle and nutritional recommendations, without the structured study exercise program or study supplementation.

Standard clinical management for transthyretin cardiac amyloidosis according to routine cardiology practice.

Placebo Comparator: Exercise + Microcrystalline Cellulose Control Supplementation

Participants performed a 12-week home-based multicomponent exercise program and received daily microcrystalline cellulose as the control supplement. The supplement was provided in sachets matched to the supplementation procedure used in the experimental arm.

A 12-week home-based multicomponent exercise program adapted from the Vivifrail model, including strength, balance, mobility, and endurance exercises tailored to individual functional capacity.

Daily oral supplementation with microcrystalline cellulose, used as a nutritionally inert control supplement to match supplementation procedures.

Experimental: Exercise + Creatine and HMB Supplementation

Participants performed the same 12-week home-based multicomponent exercise program and received daily supplementation with creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day).

A 12-week home-based multicomponent exercise program adapted from the Vivifrail model, including strength, balance, mobility, and endurance exercises tailored to individual functional capacity.

Daily oral supplementation with creatine monohydrate (3 g/day) and β-hydroxy-β-methylbutyrate (HMB, 3 g/day) for 12 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Handgrip Strength
Time Frame: Baseline and 12 weeks

Change in maximal isometric handgrip strength measured in kilograms (kg) using a calibrated handheld dynamometer (best of three attempts for the dominant hand), expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in 6-Minute Walk Test Distance
Time Frame: Baseline and 12 weeks

Change in walking capacity assessed by the 6-minute walk test, measured as the difference in total distance walked (meters) between baseline and 12 weeks.

Baseline and 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Fat Mass
Time Frame: Baseline and 12 weeks

Change in total body fat mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Skeletal Muscle Mass
Time Frame: Baseline and 12 weeks

Change in skeletal muscle mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Fat-Free Mass
Time Frame: Baseline and 12 weeks

Change in fat-free mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Phase Angle
Time Frame: Baseline and 12 weeks

Change in phase angle measured in degrees (°) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Frailty Status Assessed by the FRAIL Scale
Time Frame: Baseline and 12 weeks

Change in frailty status assessed by the FRAIL scale, a 5-item questionnaire with scores ranging from 0 to 5, where higher scores indicate greater frailty, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Short Physical Performance Battery (SPPB) Score
Time Frame: Baseline and 12 weeks

Change in Short Physical Performance Battery (SPPB) total score, ranging from 0 to 12 points, where higher scores indicate better physical performance, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Clinical Frailty Scale (CFS) Score
Time Frame: Baseline and 12 weeks

Change in frailty severity assessed by the Clinical Frailty Scale (CFS), a 9-point ordinal scale ranging from 1 (very fit) to 9 (terminally ill), where higher scores indicate greater frailty.

Baseline and 12 weeks
Change in Barthel Index Score
Time Frame: Baseline and 12 weeks

Change in functional independence assessed by the Barthel Index, scored from 0 to 100, where higher scores indicate greater independence.

Baseline and 12 weeks
Change in SARC-F Score
Time Frame: Baseline and 12 weeks

Change in sarcopenia risk assessed by the SARC-F questionnaire, with scores ranging from 0 to 10, where higher scores indicate greater sarcopenia risk.

Baseline and 12 weeks
Change in Minnesota Living With Heart Failure Questionnaire Score
Time Frame: Baseline and 12 weeks

Change in health-related quality of life assessed by the Minnesota Living With Heart Failure Questionnaire (MLHFQ), with total scores ranging from 0 to 105, where higher scores indicate worse quality of life.

Baseline and 12 weeks
Change in Charlson Comorbidity Index
Time Frame: Baseline and 12 weeks

Change in comorbidity burden assessed using the Charlson Comorbidity Index, a weighted index that accounts for the number and severity of comorbid conditions, where higher scores indicate greater comorbidity burden.

Baseline and 12 weeks
Exercise Program Adherence
Time Frame: Up to 12 weeks

Proportion (%) of prescribed exercise sessions completed, with adequate adherence defined as completion of at least 80% of prescribed sessions.

Up to 12 weeks
Supplement Adherence
Time Frame: Up to 12 weeks

Proportion (%) of planned supplement doses consumed, with optimal compliance defined as 90-110%.

Up to 12 weeks
Change in Mini Nutritional Assessment Short-Form (MNA-SF) Score
Time Frame: Baseline and 12 weeks

Change in nutritional status assessed by the Mini Nutritional Assessment Short-Form (MNA-SF), with scores ranging from 0 to 14 points, where lower scores indicate poorer nutritional status and greater risk of malnutrition.

Baseline and 12 weeks
Incidence of Intervention-Related Adverse Events
Time Frame: Up to 12 weeks

Number and type of adverse events related to exercise and/or supplementation, classified according to severity and relatedness, collected during the 12-week intervention period.

Up to 12 weeks
Rate of Supplement Discontinuation
Time Frame: Up to 12 weeks

Proportion of participants who discontinue study supplementation during the intervention period.

Up to 12 weeks
Change in Skeletal Muscle Index (SMI)
Time Frame: Baseline and 12 weeks

Change in skeletal muscle index (SMI), expressed as skeletal muscle mass normalized to height squared (kg/m²), measured using multifrequency bioelectrical impedance analysis, between baseline and 12 weeks.

Baseline and 12 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Growth Differentiation Factor 15 (GDF-15)
Time Frame: Baseline and 12 weeks

Change in serum GDF-15 concentration (ng/mL) measured by immunoassay.

Baseline and 12 weeks
Change in Soluble ST2
Time Frame: Baseline and 12 weeks

Change in serum soluble ST2 concentration (ng/mL) measured by immunoassay.

Baseline and 12 weeks
Change in Interleukin-6 (IL-6)
Time Frame: Baseline and 12 weeks

Change in serum interleukin-6 (IL-6) concentration (pg/mL) measured by immunoassay.

Baseline and 12 weeks
Change in C-Reactive Protein (CRP)
Time Frame: Baseline and 12 weeks

Change in serum C-reactive protein (CRP) concentration (mg/dL) measured by immunoassay.

Baseline and 12 weeks
Change in circulating miR-21 expression
Time Frame: Baseline and 12 weeks

Change in circulating miR-21 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in circulating miR-29 expression
Time Frame: Baseline and 12 weeks

Change in circulating miR-29 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in circulating miR-34a expression
Time Frame: Baseline and 12 weeks

Change in circulating miR-34a expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in circulating miR-155 expression
Time Frame: Baseline and 12 weeks

Change in circulating miR-155 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in PBMC Immune Polarization Profile by Flow Cytometry
Time Frame: Baseline and 12 weeks

Change in the immunophenotypic profile of peripheral blood mononuclear cells (PBMCs) assessed by multiparametric flow cytometry, including the relative abundance of cell populations with M1-like and M2-like phenotypes and their ratio.

Baseline and 12 weeks
Change in Pro-inflammatory (M1) Gene Expression Markers
Time Frame: Baseline and 12 weeks

Change in gene expression of predefined pro-inflammatory (M1-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in Anti-inflammatory (M2) Gene Expression Markers
Time Frame: Baseline and 12 weeks

Change in gene expression of predefined anti-inflammatory/regenerative (M2-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in Serum Albumin
Time Frame: Baseline and 12 weeks

Change in serum albumin concentration (g/dL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Serum Prealbumin
Time Frame: Baseline and 12 weeks

Change in serum prealbumin concentration (g/dL) between baseline and 12 weeks

Baseline and 12 weeks
Change in Vitamin D
Time Frame: Baseline and 12 weeks

Change in serum 25-hydroxyvitamin D concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Galectin-3
Time Frame: Baseline and 12 weeks

Change in serum galectin-3 concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in NT-proBNP
Time Frame: Baseline and 12 weeks

Change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration (pg/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in High-Sensitivity Troponin T
Time Frame: Baseline and 12 weeks

Change in serum high-sensitivity cardiac troponin T concentration (ng/L) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Leptin
Time Frame: Baseline and 12 weeks

Change in serum leptin concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Adiponectin
Time Frame: Baseline and 12 weeks

Change in serum adiponectin concentration (µg/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in IGF-1
Time Frame: Baseline and 12 weeks

Change in serum insulin-like growth factor 1 (IGF-1) concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Klotho
Time Frame: Baseline and 12 weeks

Change in serum Klotho concentration (pg/mL) between baseline and 12 weeks.

Baseline and 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Director: Juan Mielgo-Ayuso, PhD, Universidad de Burgos
  • Principal Investigator: José A Pérez Rivera, PhD, MD, Hospital Universitario de Burgos

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 3, 2026

Primary Completion (Actual)

September 10, 2026

Study Completion (Actual)

September 10, 2026

Study Registration Dates

First Submitted

December 17, 2025

First Submitted That Met QC Criteria

January 7, 2026

First Posted (Actual)

January 15, 2026

Study Record Updates

Last Update Posted (Actual)

September 25, 2026

Last Update Submitted That Met QC Criteria

September 22, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data that underlie the results reported in publications will be made available upon reasonable request.

IPD Sharing Time Frame

Beginning 6 months after publication and ending 5 years after publication.

IPD Sharing Access Criteria

Access to de-identified individual participant data will be granted upon reasonable request to the principal investigator. Requests must include a methodologically sound research proposal and will be evaluated for scientific merit and feasibility. Data sharing will require the execution of a data sharing agreement and will comply with applicable data protection and privacy regulations.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.